Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

被引：1

作者：

Rebuzzi, S. E. ^{[1
]}

Signori, A. ^{[2
]}

Maruzzo, M. ^{[3
]}

Tortora, G. ^{[4
]}

Galli, L. ^{[5
]}

Rizzo, M. ^{[6
]}

De Giorgi, U. ^{[7
]}

Antonuzzo, L. ^{[8
]}

Bracarda, S. ^{[9
]}

Carteni, G. ^{[10
]}

Atzori, F. ^{[11
]}

Tamberi, S. ^{[12
]}

Procopio, G. ^{[13
]}

Fratino, L. ^{[14
]}

Santoni, M. ^{[15
]}

Baldessari, C. ^{[16
]}

Astone, A. ^{[17
]}

Calabro', F. ^{[18
]}

Buti, S. ^{[19
]}

Fornarini, G. ^{[20
]}

机构：

[1] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Med Oncol Unit 1, IRCCS Osped Policlin San Martino, Genoa, Italy

[2] Univ Genoa, Sect Biostat, Dept Hlth Sci, Genoa, Italy

[3] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Med Oncol Unit 1, Padua, Italy

[4] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Gemelli, Med Oncol, IRCCS, Rome, Italy

[5] Azienda Osped Univ Pisana, Med Oncol Unit 2, Pisa, Italy

[6] IRCCS Ist Clin Sci Maugeri, Div Translat Oncol, Pavia, Italy

[7] IRCCS Ist Romagnolo Studio Tumori Dino Amadori, Dept Med Oncol, Meldola, Italy

[8] Careggi Univ Hosp, Clin Oncol Unit, Florence, Italy

[9] Azienda Osped Santa Maria, Dept Oncol, Med & Translat Oncol, Terni, Italy

[10] Azienda Osped Rilievo Nazl Cardarelli, Div Oncol, Naples, Italy

[11] Univ Cagliari, Univ Hosp, Dept Med Oncol, Monserrato, Italy

[12] Osped Infermi, Oncol Unit, Ravenna, Italy

[13] Fdn IRCCS Ist Nazl Tumori, SS Oncol Med Genitourinaria, Milan, Italy

[14] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Aviano, Italy

[15] Macerata Hosp, Oncol Unit, Macerata, Italy

[16] Univ Hosp Modena, Dept Oncol & Hemathol, Med Oncol Unit, Modena, Italy

[17] Fatebenefratelli San Pietro Hosp, Div Med Oncol, Rome, Italy

[18] San Camillo Forlanini Hosp, Div Med Oncol B, Rome, Italy

[19] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[20] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

696P

引用

页码：S709 / S709

页数：1

共 37 条

[1] Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
Rebuzzi, S. E.
Signori, A.
Buti, S.
Banna, G. L.
Murianni, V
Damassi, A.
Maruzzo, M.
Giannarelli, D.
Tortora, G.
Galli, L.
Rizzo, M.
De Giorgi, U.
Antonuzzo, L.
Bracarda, S.
Carteni, G.
Atzori, F.
Tamberi, S.
Procopio, G.
Fratino, L.
Lo Re, G.
Santoni, M.
Baldessari, C.
Astone, A.
Calabro, F.
Brunelli, M.
Porta, C.
Rescigno, P.
Basso, U.
Fornarini, G.
ESMO OPEN, 2022, 7 (06)
[2] The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.
Rebuzzi, Sara Elena
Signori, Alessio
Banna, Giuseppe Luigi L.
Buti, Sebastiano
Rescigno, Pasquale
Gemelli, Maria
Panni, Stefano
Massari, Francesco
Soraru, Mariella
Santoni, Matteo
Cortellini, Alessio
Prati, Veronica
Parra, Hector Jose Soto
Atzori, Francesco
Di Napoli, Marilena
Caffo, Orazio
Messina, Marco
Morelli, Franco
Prati, Giuseppe
Fornarini, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9).
Damassi, Alessandra
Cremante, Malvina
Fornarini, Giuseppe
Signori, Alessio
Buti, Sebastiano
Basso, Umberto
Procopio, Giuseppe
Maruzzo, Marco
Soraru, Mariella
Di Napoli, Marilena
Fratino, Lucia
Santini, Daniele
Grillone, Francesco
Ballestrin, Melissa
Dionese, Michele
Murianni, Veronica
Catalano, Fabio
Banna, Giuseppe Luigi L.
Rescigno, Pasquale
Rebuzzi, Sara Elena
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[4] Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)
Damassi, Alessandra
Cremante, Malvina
Signori, Alessio
Rebuzzi, Sara Elena
Fornarini, Giuseppe
Giudice, Giulia Claire
Maruzzo, Marco
Procopio, Giuseppe
Soraru, Mariella
Di Napoli, Marilena
Fratino, Lucia
Santini, Daniele
Grillone, Francesco
Ballestrin, Melissa
Dionese, Michele
Nasso, Cecilia
Catalano, Fabio
Murianni, Veronica
Rescigno, Pasquale
Anpalakhan, Shobana
Banna, Giuseppe Luigi
Basso, Umberto
Buti, Sebastiano
CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 126 - 133.e2
[5] Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
Bracarda, S.
Galli, L.
Maruzzo, M.
Lo Re, G.
Buti, S.
Favaretto, A.
Costanzo, F. D.
Sacco, C.
Merlano, M.
Mucciarini, C.
Zafarana, E.
Romito, S.
Maestri, A.
Giorgio, C. Giannitto
Ionta, M. T.
Turci, D.
De Giorgi, U.
Procopio, G.
Cortesi, E.
Porta, C.
ANNALS OF ONCOLOGY, 2017, 28
[6] Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Yamashita, Shimpei
Hamamoto, Shuzo
Furukawa, Junya
Fujita, Kazutoshi
Takahashi, Masayuki
Miyake, Makito
Ito, Noriyuki
Iwamoto, Hideto
Kohjimoto, Yasuo
Hara, Isao
SCIENTIFIC REPORTS, 2024, 14 (01):
[7] Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy
Nagpal, Ria
Campione, Marina
Rebuzzi, Sara Elena
Fratino, Lucia
Rescigno, Pasquale
Bracarda, Sergio
Bimbatti, Davide
De Giorgi, Ugo
Santoni, Matteo
Calabro, Fabio
Rizzo, Mimma
Signori, Alessio
Giannarelli, Diana
Fornarini, Giuseppe
Basso, Umberto
Banna, Giuseppe Luigi
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2025, 24
[8] The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (Δ-Meet-URO analysis).
Rebuzzi, Sara Elena
Signori, Alessio
Buti, Sebastiano
Banna, Giuseppe Luigi L.
Stellato, Marco
Santini, Daniele
Basso, Umberto
De Giorgi, Ugo
Chiellino, Silvia
Salfi, Alessia
Zucali, Paolo Andrea
Masini, Cristina
Naglieri, Emanuele
Procopio, Giuseppe
Milella, Michele
Boccardo, Francesco
Fratino, Lucia
Pipitone, Stefania
Porta, Camillo
Fornarini, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
Sabbatini, R.
Galli, L.
Pignata, S.
Lo Re, G.
Valcamonico, F.
Defferrari, C.
Spada, M.
Santini, D.
Masini, C.
Ciuffreda, L.
Ruggeri, E. M.
Chioni, A.
Livi, L.
Fagnani, D.
Bonetti, A.
Giustini, L.
Duranti, S.
Procopio, G.
Caserta, C.
Carteni, G.
ANNALS OF ONCOLOGY, 2017, 28
[10] Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
Rebuzzi, Sara Elena
Signori, Alessio
Banna, Giuseppe Luigi
Maruzzo, Marco
De Giorgi, Ugo
Pedrazzoli, Paolo
Sbrana, Andrea
Zucali, Paolo Andrea
Masini, Cristina
Naglieri, Emanuele
Procopio, Giuseppe
Merler, Sara
Tomasello, Laura
Fratino, Lucia
Baldessari, Cinzia
Ricotta, Riccardo
Panni, Stefano
Mollica, Veronica
Soraru, Maria
Santoni, Matteo
Cortellini, Alessio
Prati, Veronica
Soto Parra, Hector Jose
Stellato, Marco
Atzori, Francesco
Pignata, Sandro
Messina, Carlo
Messina, Marco
Morelli, Franco
Prati, Giuseppe
Nole, Franco
Vignani, Francesca
Cavo, Alessia
Roviello, Giandomenico
Pierantoni, Francesco
Casadei, Chiara
Bersanelli, Melissa
Chiellino, Silvia
Paolieri, Federico
Perrino, Matteo
Brunelli, Matteo
Iacovelli, Roberto
Porta, Camillo
Buti, Sebastiano
Fornarini, Giuseppe
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

← 1 2 3 4 →